EMulate Therapeutics, Inc. has developed a patented (40+ issued patents to date), proprietary technology using ulRFE® to produce therapeutic biological effects that have been demonstrated in plants, animals and now in humans. EMulate’s ulRFE technology produces a broadband, multifrequency oscillating magnetic field, with frequencies from 0 kHz up to roughly 22 kHz, that is obtained from recordings of selected molecules derived using its proprietary Magnetic Interrogation Device System or “MIDS.” While the details of the mechanism of action are not fully understood, recordings are hypothesized to capture noncovalent features of the recorded molecule that alter cellular behavior. EMulate’s ulRFE technology is currently in clinical testing for adults and children with terminal brain cancer, using an oscillating magnetic field created by its ulRFE technology, derived from the molecule paclitaxel. The technology is also in preclinical testing and in initial human testing, using oscillating magnetic fields derived from other specific molecules, for use in patients suffering from chronic or acute pain and from central nervous system disorders.